REG - LungLife AI, INC - Enrolment completed for LungLB® validation study

LungLife AIAnnouncement

23/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230523:nRSW2575Aa&default-theme=true

RNS Number : 2575A  LungLife AI, INC  23 May 2023

LungLife AI, Inc.

(the "Company" or "LungLife")

 

Enrolment completed for pivotal validation study of LungLB®

 

Company to work with clinical sites to ensure data quality ahead of analysis
and readout

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, announces the completion of enrolment for its prospective, pivotal
validation study of LungLB®. Since February 2022, 425 study participants have
been enrolled from seventeen sites across the United States from leading
academic medical centres and Veterans Affairs hospitals.

 

The Company is now focused on preparing the data for detailed analysis,
including working with each clinical site to finalise monitoring of study data
before it is unblinded. Monitoring ensures complete, accurate, and
high-quality information will be received for all participants in the study
prior to final analyses and results interpretation. In line with expectations,
the Company estimates this process will take between 3-4 months, at which
point the study results are expected to be known. Following this, the Company
will seek to publish the study findings in a peer-reviewed medical journal.

 

Commenting, Paul Pagano, Chief Executive Officer of LungLife, said:
"Completing enrolment is a considerable milestone along the path to
commercialisation, and we are pleased that we continue to remain on-track with
the timeline set out at IPO. We would like to thank our clinical investigators
and their teams, and importantly the study participants, for taking part in
our trial and for their continued support with study close-out."

 

 

For further information please contact:

 

 LungLife AI, Inc.                                       www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                        Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Broker)          Tel: +44 (0)20 7597 5970
 Virginia Bull / Cameron MacRitchie / Lydia Zychowska

 Goodbody (Joint Broker)                                 Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420
 Tom Nicholson / Stephen Kane

 Walbrook PR Limited                                      Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
                                                         (mailto:LungLifeAI@walbrookpr.com)
 Stephanie Cuthbert / Alice Woodings / Phillip Marriage  Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

 

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

 

Our Purpose is to be a driving force in the early detection to lung cancer.
And our Vision is to invert the 20:80 ratio such that in years to come at
least 80% of lung cancer is detected early.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESBRGDUUBDDGXD